Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.

Journal Article (Clinical Trial;Journal Article)

BACKGROUND: The durability and breadth of human immunodeficiency virus type 1 (HIV-1)-specific immune responses elicited through vaccination are important considerations in the development of an effective HIV-1 vaccine. Responses to HIV-1 envelope subunit protein (Env) immunization in humans are often described as short-lived. METHODS: We enrolled 16 healthy volunteers who had received priming with an HIV-1 subtype B Env vaccine given with MF59 adjuvant 5-17 years previously and 20 healthy unprimed volunteers. Three booster immunizations with a heterologous subtype C trimeric gp140 protein vaccine were administered to the primed group, and the same subtype C gp140 protein vaccination regimen was administered to the unprimed subjects. RESULTS: Binding antibodies and neutralizing antibodies to tier 1 viral isolates were detected in the majority of previously primed subjects. Remarkably, a single dose of protein boosted binding and neutralizing antibody titers in 100% of primed subjects following this prolonged immunologic rest period, and CD4+ T-cell responses were boosted in 75% of primed individuals. CONCLUSIONS: These results demonstrate that HIV-1 protein immunogens can elicit durable memory T- and B-cell responses and that strong tier 1 virus neutralizing responses can be elicited by a single booster dose of protein following a long immunologic rest period. However, we found no evidence that cross-clade boosting led to a significantly broadened neutralizing antibody response.

Full Text

Duke Authors

Cited Authors

  • Spearman, P; Tomaras, GD; Montefiori, DC; Huang, Y; Elizaga, ML; Ferrari, G; Alam, SM; Isaacs, A; Ahmed, H; Hural, J; McElrath, MJ; Ouedraogo, L; Pensiero, M; Butler, C; Kalams, SA; Overton, ET; Barnett, SW; HVTN 088 Protocol Team and the NIH/NIAID HIV Vaccine Trials Network,

Published Date

  • May 5, 2019

Published In

Volume / Issue

  • 219 / 11

Start / End Page

  • 1755 - 1765

PubMed ID

  • 30615119

Pubmed Central ID

  • PMC6775047

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiz008


  • eng

Conference Location

  • United States